Dynavax Technologies Corporation (NASDAQ:DVAX) Receives $24.33 Average Price Target from Analysts

Dynavax Technologies Corporation (NASDAQ:DVAX) has been given an average recommendation of “Hold” by the five analysts that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $24.3333.

Several analysts have issued reports on DVAX shares. Wall Street Zen raised Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 27th. Weiss Ratings reissued a “sell (d)” rating on shares of Dynavax Technologies in a research report on Wednesday, January 21st. Finally, William Blair cut Dynavax Technologies from an “outperform” rating to a “hold” rating in a research note on Wednesday, December 24th.

Insider Activity at Dynavax Technologies

In other news, COO David F. Novack sold 114,000 shares of the business’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $15.64, for a total value of $1,782,960.00. Following the sale, the chief operating officer owned 63,344 shares of the company’s stock, valued at $990,700.16. The trade was a 64.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.98% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Dynavax Technologies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DVAX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Dynavax Technologies by 1.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 86,421 shares of the biopharmaceutical company’s stock worth $1,126,000 after buying an additional 1,625 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Dynavax Technologies in the first quarter valued at about $180,000. Caxton Associates LLP bought a new stake in Dynavax Technologies during the first quarter worth about $225,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Dynavax Technologies by 7.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 450,089 shares of the biopharmaceutical company’s stock valued at $5,838,000 after purchasing an additional 29,764 shares during the last quarter. Finally, Blair William & Co. IL boosted its position in Dynavax Technologies by 0.3% during the second quarter. Blair William & Co. IL now owns 2,279,647 shares of the biopharmaceutical company’s stock valued at $22,614,000 after purchasing an additional 6,940 shares during the last quarter. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Stock Performance

Shares of DVAX stock opened at $15.50 on Thursday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.94 and a current ratio of 7.62. Dynavax Technologies has a 52 week low of $9.20 and a 52 week high of $15.73. The company’s 50 day moving average price is $13.93 and its two-hundred day moving average price is $11.66. The company has a market capitalization of $1.82 billion, a P/E ratio of -41.89 and a beta of 0.97.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.07. Dynavax Technologies had a negative net margin of 13.13% and a positive return on equity of 7.18%. The company had revenue of $94.88 million during the quarter, compared to analysts’ expectations of $94.00 million. On average, analysts expect that Dynavax Technologies will post 0.32 earnings per share for the current fiscal year.

About Dynavax Technologies

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.